FibroNox is focused on developing patented first-in-class therapeutics to treat and reverse life-threatening fibrotic diseases. FibroNox has pioneered the development of selective Nox4 inhibitors and Nrf2 activators that have shown robust protection from fibrosis development and promoted the reversal of age-associated established fibrosis. FibroNox’s initial focus is treating idiopathic pulmonary fibrosis and fibrosis in Duchenne muscular dystrophy. FibroNox’s therapeutics offer the opportunity to reverse age-associated established fibrosis, representing the holy grail for more effective strategies to treat fibrotic diseases.
Company Details
- Employees
- 2
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.fibronox.com
- Keywords
- New York.
Fibronox, Inc. Questions
Fibronox, Inc.'s website is http://www.fibronox.com
Fibronox, Inc.'s LinkedIn profile is https://www.linkedin.com/company/fibronox-inc
Fibronox, Inc. has
2 employees.
View email and phone details for 2
employees at Fibronox, Inc..
Fibronox, Inc.'s industry is
Biotechnology Research
Fibronox, Inc.'s top competitors are
Percheron Therapeutics Limited,
Fibrofind,
Epirium Bio,
Aavogen,
Sarcomatrix,
Sqy Therapeutics,
Odessa Brand House,
The Extracellular Matrix Pharmacology Congress,
Genvade Therapeutics,
Elenae Therapeutics, Inc..
Fibronox, Inc.'s categories are Biotechnology Research
Fibronox, Inc.'s founding year is 2023
